VICTORIA, Sept. 1, 2017 /CNW/ - Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) ("Emerald" or the "Company") announces that it has engaged PCG Advisory Group ("PCG"), a New York, New York based investor relations firm, to provide investor relations and strategic communications services to the Company, subject to TSX Venture Exchange acceptance.

PCG has been engaged for an initial term of six months and will be entitled to receive a monthly fee of US$6,500. The agreement will automatically renew on a monthly basis following the initial term and may be terminated by the Company upon 30 days' notice following the initial term. In addition, the Company has agreed to a one-time grant of options to purchase up to 100,000 shares of the Company exercisable for a period of 5 years at a price equal to the closing price of the common shares on the TSX Venture Exchange on the date of issuance. The options shall become vested and exercisable in equal quarterly instalments over 2 years, provided that PCG is continuing to provide services on the date of each vesting increment. The options shall be subject to the applicable policies of the TSX Venture Exchange.

PCG currently has no direct or indirect interest in the securities of the Company, or any right or intent to acquire such an interest except pursuant to the exercise of the above referenced options.

The appointment of PCG as an investor relations consultant of the Company and the granting of the options remain subject to regulatory acceptance of applicable filings with the TSX Venture Exchange.

About Emerald Health Therapeutics, Inc.

Emerald operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Botanicals is authorized to produce and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor facility in Victoria, British Columbia, with plans for expansion on a 32-acre property in Metro Vancouver and a joint venture with Village Farms utilizing 25 acres of greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed producers, with a team of highly qualified management experienced in pharmaceutical drug discovery, development and distribution. Emerald's vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics and intellectual property, value added products and branding, and superb customer experience.

Please visit https://www.emeraldhealth.ca/ for more information.

About PCG Advisory Group

Founded in 2008 and headquartered in New York City, PCG Advisory Group is dedicated to the delivery of top tier investor relations, strategic advisory, communications, and innovative digital media services for the micro and small cap public company marketplace. PCG has extensive experience with life sciences, technology, energy and other emerging growth companies, both in the US and internationally. PCG's team of senior level professionals bring many years of direct advisory experience, along with unique and high quality relationships amongst the investment and media communities. PCG's primary focus is building a shareholder base and expanding market awareness through very professional methods and initiatives. PCG's Capital Markets Advisory Services include overall investor marketing and communications strategy development to increase and leverage awareness, visibility and credibility. PCG's Social and Digital Media services include maximizing social and professional digital media channels to effectively and accurately communicate clients' specific opportunities. www.pcgadvisory.com

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements regarding the Company's plans for expansion; and the Company's vision to be a leading provider of cannabis.

The Company does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the potential offering of any securities by the Company; variations in market conditions; failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company's annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com . Actual results may differ materially from those expressed or implied by such forward-looking statements

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

SOURCE Emerald Health Therapeutics, Inc.

For further information: Sandy Pratt, CFO, Emerald Health Therapeutics, Inc., P: 250-818-9838, E: [email protected]

Related Links

https://www.emerald.care/

